Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries and Israel-based Moebius Medical announced today the publication of two articles in Osteoarthritis and Cartilage, the official journal of the Osteoarthritis Research Society International (OARSI), highlighting MM-II, a novel non-opioid product for the treatment of symptomatic knee osteoarthritis. MM-II is based on a proprietary suspension of large, empty, multilamellar liposomes designed to reduce joint friction and wear, thereby alleviating pain. The two publications offer complementary insights into MM-II's clinical efficacy and mechanism of action, underscoring its potential therapeutic value. The first publication presents results from a Phase 2b randomized, double-blind, placebo-controlled trial (NCT04506463), which enrolled 397 patients across the US, Europe and Asia. Findings demonstrate that a single injection of MM-II provided clinically meaningful pain relief through 26 weeks, with a favorable safety and tolerability profile. The second publication, titled 'Empty large liposomes reduce cartilage degeneration in osteoarthritic rats by forming a lubricative coating,' details MM-II's unique mechanism of action. The research shows that MM-II forms a lubricative layer over cartilage surfaces, reducing friction and slowing cartilage degeneration. The authors suggest that the results of the clinical trial may be mediated through the coating of the cartilage surfaces, though additional mechanisms may contribute to the long term pain reduction seen in Phase 2b study. 'The data from these publications show that MM-II has the potential to provide durable pain relief for patients,' said Prof. Thomas J Schnitzer, MD, PhD, a rheumatologist and professor of Medicine at Northwestern University and lead author of the clinical trial manuscript. 'With limited treatment options, lack of novel treatment approaches, and concerns around opioid use, MM-II may offer a promising alternative to hyaluronic acid and steroid treatments.' Powered by Capital Market - Live

Sun Pharmaceutical Industries announced that on 09 April 2025, the U.S. Court of Appeals for the Federal Circuit held an oral argument on the Company's appeal of the U.S. District Court for the District of New Jersey's decision that previously granted a preliminary injunction delaying the Company's launch of LEQSELVI' (deuruxolitinib) in the United States. Shortly after the oral argument concluded, on 09 April 2025, the U.S. Court of Appeals for the Federal Circuit ruled in favour of the Company and vacated the preliminary injunction effective immediately. While the litigation between Incyte Corporation and the Company continues, the preliminary injunction is no longer in effect. The Company is no longer under a court order that delays or restricts the Company from launching LEQSELVI'. The Company will disclose LEQSELVI' launch plans in due course of time.Powered by Capital Market - Live

The drug, available in 40 mg tablets, is approved as a new treatment for adults with erosive esophagitis of all grades. FEXUCLUE, containing Fexuprazan, is primarily used to treat acid-related disorders, including gastroesophageal reflux disease (GERD) and erosive esophagitis. It is also being studied for the prevention of NSAID-induced peptic ulcers and gastritis. Sun Pharma has obtained the rights from Daewoong Pharmaceutical, a South Korean biopharmaceutical company, to manufacture and commercialize FEXUCLUE in India. As part of the agreement, Daewoong will receive upfront and milestone payments, as well as royalties. Kirti Ganorkar, CEO of India Business, Sun Pharma, said, 'Erosive esophagitis is a serious condition that greatly affects patients' quality of life. Despite available treatments, there remains a significant unmet need in its management. FEXUCLUE is a best-in-class treatment option with the potential to bridge this gap. At Sun Pharma, we are committed to introducing innovative medicines that enhance patients' quality of life. Sun Pharmaceuticals Industries is a leading global pharmaceutical company with a specialty and generic presence and India's top pharma company. The pharma major's consolidated net profit increased 15.04% to Rs 2,903.38 crore on a 10.46% rise in revenue from operations to Rs 13,675.46 crore in Q3 FY25 over Q3 FY24. Shares of Sun Pharmaceuticals Industries fell 3.47% to Rs 1,650 on the BSE.Powered by Capital Market - Live

Sun Pharmaceutical Industries has launched Fexuprazan tablets 40 mg in India under the brand name 'FEXUCLUE''. FEXUCLUE', a novel potassium competitive acid blocker (PCAB), is approved as a new treatment for adults with Erosive Esophagitis of all grades. Sun Pharma has obtained rights from Daewoong Pharmaceutical Co Ltd, Korea, a biopharmaceutical company, to manufacture and commercialise FEXUCLUE'(Fexuprazan) in India. As per agreement terms, Daewoong will be entitled to upfront and milestone payments, including royalties.Powered by Capital Market - Live

Sun Pharmaceutical Industries has completed 100% acquisition of Antibe Therapeutics Inc., Canada for a total consideration of CAD 4.5 million. Powered by Capital Market - Live

Sun Pharmaceuticals Industries is a leading global pharmaceutical company with a specialty and generic presence and India's top pharma company. The pharma major's consolidated net profit increased 15.04% to Rs 2,903.38 crore on a 10.46% rise in revenue from operations to Rs 13,675.46 crore in Q3 FY25 over Q3 FY24Powered by Capital Market - Live

Sun Pharmaceuticals Industries Ltd rose for a fifth straight session today. The stock is quoting at Rs 1699.6, up 0.96% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.31% on the day, quoting at 22466.9. The Sensex is at 74002.67, up 0.24%. Sun Pharmaceuticals Industries Ltd has dropped around 0.12% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceuticals Industries Ltd is a constituent, has dropped around 1.58% in last one month and is currently quoting at 20386.85, up 1.23% on the day. The volume in the stock stood at 14.7 lakh shares today, compared to the daily average of 22.43 lakh shares in last one month. The benchmark March futures contract for the stock is quoting at Rs 1699.9, up 0.91% on the day. Sun Pharmaceuticals Industries Ltd is up 8.17% in last one year as compared to a 1.86% gain in NIFTY and a 9.69% gain in the Nifty Pharma index.The PE of the stock is 128.24 based on TTM earnings ending December 24.Powered by Capital Market - Live

Sun Pharmaceuticals Industries Ltd is up for a third straight session today. The stock is quoting at Rs 1673.25, up 1.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.71% on the day, quoting at 22337.55. The Sensex is at 73661.95, down 0.59%. Sun Pharmaceuticals Industries Ltd has slipped around 4.19% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceuticals Industries Ltd is a constituent, has slipped around 5.49% in last one month and is currently quoting at 20332.1, down 0.4% on the day. The volume in the stock stood at 11.98 lakh shares today, compared to the daily average of 22.91 lakh shares in last one month. The benchmark March futures contract for the stock is quoting at Rs 1674.7, up 1.07% on the day. Sun Pharmaceuticals Industries Ltd is up 7.36% in last one year as compared to a 1.54% jump in NIFTY and a 8.67% jump in the Nifty Pharma index.The PE of the stock is 126.1 based on TTM earnings ending December 24.Powered by Capital Market - Live

Checkpoint is a Nasdaq-listed commercial-stage company focused on developing novel treatments for patients with solid tumor cancers. For the nine-month period ending September 2024, Checkpoint reported $0.04 million in revenue and a net loss of $27.3 million. Checkpoint has received approval from the U.S. Food & Drug Administration (FDA) for UNLOXCYT (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Cutaneous Squamous Cell Carcinoma (cSCC) is the second-most common type of skin cancer in the United States, with an estimated annual incidence of approximately 1.8 million cases according to the Skin Cancer Foundation. As per the terms of the contract, Sun Pharma will acquire all outstanding shares of Checkpoint and Checkpoint stockholders will receive, for each share of common stock they hold, an upfront cash payment of $4.10, without interest, and a non-transferable contingent value right (CVR) entitling the stockholder to receive up to an additional $0.70 in cash, without interest, if cosibelimab is approved prior to certain deadlines in the European Union pursuant to the centralized approval procedure or in Germany, France, Italy, Spain or the United Kingdom, subject to the terms and conditions in the contingent value rights agreement. The upfront cash payment of $4.10 per share of common stock represents a premium of approximately 66.0% to Checkpoint's closing share price on March 7, 2025, the last trading day prior to today's announcement. In connection with the transaction, Checkpoint, Sun Pharma and Fortress Biotech, Inc., Checkpoint's controlling stockholder, have entered into a royalty agreement, under which following the closing of the transaction Fortress would be entitled to receive royalty payments based on future sales of cosibelimab during a specified term, in lieu of royalty rights that were granted to Fortress in connection with its founding of Checkpoint. The transaction is expected to be completed in the second calendar quarter of 2025. Dilip Shanghvi, chairman & managing director of Sun Pharma, said: 'Combining UNLOXCYT, an FDA approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma, with Sun Pharma's global presence means patients with cSCC may soon have access to an important, new treatment option. The acquisition further bolsters our innovative portfolio in onco-derm therapy.' Sun Pharmaceuticals Industries is a leading global pharmaceutical company with a specialty and generic presence and India's top pharma company. The pharma major's consolidated net profit increased 15.04% to Rs 2,903.38 crore on 10.46% rise in revenue from operations to Rs 13,675.46 crore in Q3 FY25 over Q3 FY24. The scrip was down 0.06% to currently trade at Rs 1609 on the BSE. Powered by Capital Market - Live

Sun Pharmaceutical Industries and Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) (Checkpoint) today announced that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an immunotherapy and targeted oncology company. Checkpoint is a Nasdaq-listed commercial-stage company focused on developing novel treatments for patients with solid tumor cancers. Checkpoint has received approval from the U.S. Food & Drug Administration (FDA) for UNLOXCYT' (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Upon completion of the transaction, Sun Pharma will acquire all outstanding shares of Checkpoint and Checkpoint stockholders will receive, for each share of common stock they hold, an upfront cash payment of $4.10, without interest, and a non-transferable contingent value right (CVR) entitling the stockholder to receive up to an additional $0.70 in cash, without interest, if cosibelimab is approved prior to certain deadlines in the European Union pursuant to the centralized approval procedure or in Germany, France, Italy, Spain or the United Kingdom, subject to the terms and conditions in the contingent value rights agreement. The upfront cash payment of $4.10 per share of common stock represents a premium of approximately 66.0% to Checkpoint's closing share price on 07 March 2025, the last trading day prior to today's announcement. The transaction is expected to be completed in the second calendar quarter of 2025. The transaction is subject to customary closing conditions, including required regulatory approvals and approval by the holders of a majority of the voting power of outstanding shares of Checkpoint common stock, and by the holders of a majority of the shares of Checkpoint common stock that are not held by Fortress or by certain other affiliates of Checkpoint. For the nine-month period ending September 2024, Checkpoint reported $0.04 million in revenue and a net loss of $27.3 million. The R&D expense for the nine-month period was $19.3 million. As of September 30, 2024, Checkpoint had a cash balance of $4.7 million, outstanding accounts payable and accrued expenses of $15.6 million, and outstanding accounts payable and accrued expenses -related party of $2.0 million. In connection with the transaction, Fortress, which holds a majority of Checkpoint's outstanding voting power, has agreed to vote in favor of the transaction.Powered by Capital Market - Live